Project Grant F99CA294132
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$104K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Detroit, MI 48201, USA
Similar Awards
The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, awarded a $342,397 Project Grant to Wayne State University to investigate the relationship between MAIT cells and the microbiome in pancreatic cancer liver metastasis. The award period runs from September 30, 2024 to April 28, 2028. The Cancer Research Manpower program supports diverse cancer-related research, training, and career development initiatives across academic and medical...
This $128,199 Project Grant, awarded on August 14, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower), supports research to determine the role of the lipid kinase PIKFYVE in regulating metabolic homeostasis in pancreatic ductal adenocarcinoma (PDAC) and explore the synergistic effects of inhibiting PIKFYVE and the KRAS-MAPK signaling pathway. The research aims to delineate the functional relationship between PIKFYVE and lipid homeostasis in PDAC, establish a rationale...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $636,046 to the Weill Medical College of Cornell University to conduct research aimed at defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants. The key products and services to be delivered under this 5-year award, which began on November 25, 2024, include: Deciphering how cell lineage impacts the neoplastic transformation and molecular...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $523,480.00 to the Dana-Farber Cancer Institute, Inc. to conduct research aimed at overcoming resistance to KRAS inhibitor therapies in pancreatic ductal adenocarcinoma (PDAC). The research will focus on defining how dysregulated iron metabolism and autophagy-dependent mechanisms contribute to both acute adaptive and long-term acquired resistance to KRAS inhibition in PDAC. The goal is to...
The National Cancer Institute (NCI) awarded a $159,540 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of North Carolina at Chapel Hill. The grant supports research to mechanistically examine and inhibitor target nutrient scavenging processes, including macropinocytosis and autophagy, for the treatment of pancreatic cancer. The research aims to understand how inhibitors of the KRAS-ERK MAPK pathway regulate these metabolic processes over time, and...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $698,008 to The Trustees of the University of Pennsylvania to conduct research on the regulation of histone propionylation in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanism by which branched-chain amino acid metabolism generates nuclear propionyl-CoA to modulate histone propionylation and gene expression, with the goal...
This $657,776 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The award will fund comprehensive characterization and evaluation of this novel agent's anti-tumor activity using a wide range of tumor models. The objective is to develop a tumor-selective, safe, and highly potent pan-RAS inactivator that has high clinical utility for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $642,755 to The Institute For Cancer Research (ICR) to conduct research on targeting the protein Anoctamin 6 (ANO6) to disrupt the process of trogocytosis between cancer-associated fibroblasts (CAFs) and pancreatic ductal adenocarcinoma (PDAC) tumor cells. The key objectives are to understand how ANO6 activity is regulated in the CAF-cancer cell interface, determine how blocking...
This $1,130,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed anti-Tn (AREMAB6) monoclonal antibody. The key objectives are to: 1) determine how the Tn antigen enhances PDAC progression and identify Tn-expressing glycoproteins; 2) validate the role of natural killer cells in AREMAB6-mediated...